TLR7 and Hyperkeratosis: As expected, the application of the TLR7 agonist IMQ resulted in erythematosus, thickened and scaly psoriasis-like dermatitis (Figure 2A), as confirmed by histological observation of hyperkeratosis, dyskeratosis, acanthosis, and dermal inflammatory cell infiltration (Figure 2B).